Trinity Biotech plc Stock price

Equities

TRIB

US8964385046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.98 USD -1.98% Intraday chart for Trinity Biotech plc -10.00% -7.69%
Sales 2021 92.96M Sales 2022 74.78M Capitalization 37.73M
Net income 2021 - Net income 2022 -41M EV / Sales 2021 1.11 x
Net Debt 2021 73.28M Net Debt 2022 65.62M EV / Sales 2022 1.38 x
P/E ratio 2021
38.2 x
P/E ratio 2022
-0.81 x
Employees 398
Yield 2021 *
-
Yield 2022
-
Free-Float 89.35%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Trinity Biotech Says it Regained Compliance With Nasdaq's Minimum Bid Price Rule MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
More news
1 day-1.98%
1 week-10.00%
Current month-9.17%
1 month-13.91%
3 months+1.54%
6 months-44.37%
Current year-7.69%
More quotes
1 week
1.98
Extreme 1.98
2.22
1 month
1.98
Extreme 1.98
2.48
Current year
1.98
Extreme 1.98
3.35
1 year
1.85
Extreme 1.85
6.20
3 years
1.85
Extreme 1.85
22.05
5 years
1.85
Extreme 1.85
34.11
10 years
1.85
Extreme 1.85
130.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 20-11-16
Founder 68 92-05-31
Chief Operating Officer - 20-12-31
Members of the board TitleAgeSince
Founder 68 92-05-31
Director/Board Member 65 95-09-30
Director/Board Member 66 22-10-25
More insiders
Date Price Change Volume
24-03-27 1.98 -1.98% 12,359
24-03-26 2.02 -4.27% 23,335
24-03-25 2.11 -0.47% 21,184
24-03-22 2.12 -1.40% 6,044
24-03-21 2.15 -2.27% 42,710

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot, EZ and EZ. It supplies this market with other products through its clinical chemistry business. It manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock
  2. Equities
  3. Stock Trinity Biotech plc - Nasdaq